Double Digit NASDAQ Stock Winners: NAOV, GOCO, TVTX

8:11 am Tuesday, August 17th, 2021

Following are major stock gainers on Nasdaq in Monday’s trading session:

NanoVibronix, Inc. (NASDAQ:NAOV) was the active stock gainer on Monday and soared 34% to $3.37 after the company announced that it intends to enter the Over-the-Counter (OTC) pain relief market with the introduction of PainShield RELIEF™, a non-prescription ultrasound therapy device that delivers fast pain relief for nerve and soft tissue damage.

The company has submitted its trademark application to the U.S. Patent and Trademark Office (USPTO) for protection of the PainShield RELIEF and expects to submit for clearance to the U.S. Food and Drug Administration (FDA) in the very near term.

GoHealth, Inc. (NASDAQ:GOCO) was another notable winner as the stock went up 22% to end the session at $4.97. Second quarter 2021 net revenue of $196.9 million increased 55% compared to the prior year period. YTD 2021 net revenue of $401.1 million increased 50% compared to the prior year period.

Second quarter 2021 net loss of $39.2 million compared to a net loss of $22.9 million in the prior year period; Adjusted EBITDA1 of $14.3 million decreased 47% compared to the prior year period due to the 2021 strategic investments in agent capacity, marketplace technology, branding and the Encompass Platform. YTD 2021 net loss was $46.4 million compared to a net loss of $23.8 million in the prior year period; Adjusted EBITDA1 of $46.4 million decreased 25% compared to the prior year period.

Travere Therapeutics, Inc. (NASDAQ:TVTX) surged 15% to $17.82 after the company announced positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan, an investigational product candidate for the treatment of IgA nephropathy (IgAN). The PROTECT Study met its pre-specified interim primary efficacy endpoint with statistical significance, demonstrating a greater than threefold reduction of proteinuria from baseline after 36 weeks of treatment, compared to the active control irbesartan (p<0.0001).